linjc16/ctgov huggingface dataset:
Troponin Elevation in Consecutive Patients With Hip Fracture

Study Overview
=================
Brief Summary
-----------------
The aims of this study is to study the occurrence of the troponin elevations, ECG changes, and cardiac symptoms in unselected consecutive patients with hip fracture. Followup will be carried out up to one year period.

Official Title
-----------------
Troponin Elevation in Consecutive Patients With Hip Fracture

Conditions
-----------------
Hip Fracture

Intervention / Treatment
-----------------
* Other: observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criterion: Hip fracture diagnosed in Turku Univeristy Hospital between October 2009 and May 2010 Exclusion Criterion: Patient refusal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with hip fracture<br> | Other: observation<br>* observation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients with hip fracture
Bariatric Surgery and Pharmacokinetics of Gabapentin

Study Overview
=================
Brief Summary
-----------------
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on gabapentin are investigated.

Official Title
-----------------
Bariatric Surgery and Pharmacokinetics Gabapentin: BAR-MEDS Gabapentin

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Drug: Gabapentin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway Being a Norwegian citizen Exclusion Criteria: Having previously undergone resections in the GI-tract

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gabapentin|Patients are tested for their normal prescription gabapentin medication|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| gabapentin concentration in blood serum (area under curve (AUC)) |  | From baseline to 1 year postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bariatric surgery, Gastrointestinal tract, Biological availability, Pharmacokinetics, Gabapentin
Association of Inpatient Blood Pressure Levels With In-hospital Adverse Events(APPLE Study)

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate the association between inpatient blood pressure levels and in-hosopital adverse outcomes.

Detailed Description
-----------------
Study population includes subjects who are hospitalized due to illness, of any race or ethnicity, any of age.The primary outcome is all-cause mortality occured in the hospital.

Official Title
-----------------
Association of Inpatient Blood Pressure Levels With In-hospital Adverse Events(APPLE Study)

Conditions
-----------------
Blood Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inpatient with all age or race; Have blood pressure data. Exclusion Criteria: Non-patients； Death outside the hospital； Missing blood pressure data.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality | All-cause mortality was confirmed through a combination of hospital medical records. | during the procedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood Pressure, Inpatient, Adverse Events, All-cause mortality
Irofulven in Treating Patients With Stage IV Melanoma

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irofulven in treating patients who have stage IV melanoma.

Detailed Description
-----------------
OBJECTIVES: I. Determine the response rate and duration of response in patients with stage IV malignant melanoma treated with 6-hydroxymethylacylfulvene. II. Determine the toxicity of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive 6-hydroxymethylacylfulvene IV over 5 minutes on days 1-5. Treatment repeats every 4 weeks for a minimum of 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease after completion of course 2 receive additional courses. Patients are followed every 3 months for 5 years, and then annually thereafter until death. PROJECTED ACCRUAL: Approximately 16-35 patients will be accrued for this study within 1 year.

Official Title
-----------------
A Multicenter Phase II Trial of MGI-114 in Patients With Stage IV Malignant Melanoma

Conditions
-----------------
Melanoma (Skin)

Intervention / Treatment
-----------------
* Drug: irofulven


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Histologically proven stage IV malignant melanoma No prior chemotherapy OR No more than 1 prior chemotherapy containing regimen Measurable disease Brain metastasis allowed if adequately treated PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: Hemoglobin at least 10 g/dL WBC at least 4,000/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) ALT/AST no greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: See Disease Characteristics Recovered from any prior therapy No other concurrent therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: irofulven|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stage IV melanoma
Music for Dementia-related Sleep Problems

Study Overview
=================
Brief Summary
-----------------
The study aims to evaluate the effect of listening to music at bedtime on sleep in elderly persons with dementia and sleep problems.

Detailed Description
-----------------
The study is a clinical trial to assess the effect of music listening as intervention for improving sleep in elderly persons with dementia and sleep problems. We use a within-subject design to evaluate the effect of the music intervention. Participants are persons above the age of 60 diagnosed with dementia and suffering from sleep problems. We will examine the effect of the intervention on sleep, mood and cognition.

Official Title
-----------------
Dementia and Sleep

Conditions
-----------------
Dementia, Insomnia

Intervention / Treatment
-----------------
* Behavioral: Music


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dementia Sleep problems Exclusion Criteria: Use of hypnotic medications Substance abuse Severe hearing deficits Not out of bed during daytime

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Within-subject design
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Music<br>Daily music listening for 30 minutes at bedtime | Behavioral: Music<br>* Listening to music for 30 minutes at bedtime<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep | Change in sleep pattern measured objectively with wrist actigraphy | 14 days baseline and 14 days intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sleep quality | Change in sleep quality reported by primary caregiver (5 point Likert scale: 0=no change - 4=extreme change) | After 14 days intervention period | 
| Depression | Change in depressive symptoms as measured by the Geriatric Depression Scale (GDS). Scoring range 0-15. 0-4=no depression, 5-7=potential depression, >8=probable depression. | Measured at baseline and after 14 days intervention period | 
| Cognition | Change in cognitive functioning as measured by the Mini-Mental-State Examination (MMSE) | Measured at baseline and after 14 days intervention period | 
| Mood | Change in mood as reported by primary caregiver (5 point Likert scale: 0= no change - 4=extreme change) | After 14 days intervention period |
Efficacy and Tolerability of Xalatan in Patients

Study Overview
=================
Brief Summary
-----------------
Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

Detailed Description
-----------------
Efficacy data not collected or analyzed Safety and tolerability of Xalatan assessed NA

Official Title
-----------------
Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Drug: Xalatan 0.005% eye drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with ocular hypertension at least 22mg Hg Patient must be over 18 years old Exclusion Criteria: None listed in the protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Study Drug - Xalatan 0.005% eye drops<br> | Drug: Xalatan 0.005% eye drops<br>* ophthalmic solution dosed once daily for 3 months<br>* Other names: latanoprost;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraocular Pressure | Intraocular pressure was measured at each visit | Screening, 10 days, 4 weeks and 12 weeks after beginning treatment | 
| Humphrey Perimetry Visual Field | Analysis of visual field deficits for abnormalities. | Visits 1 and 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
observational safety study
Risk of Stroke in Pulmonary Embolism With a Patent Foramen Ovale (PFO)

Study Overview
=================
Brief Summary
-----------------
Pulmonary embolism is associated with a small but definite risk of paradoxical embolism in patients with a patent foramen ovale (PFO). While neurologic complications are unfrequent the incidence of clinically silent brain infarction is unknown. We will assess the rate of clinically apparent and silent cerebral embolism in patients with a pulmonary embolism (PE) in relation to the presence or not of a PFO.

Official Title
-----------------
Silent Cerebral Infarcts in Patients With Pulmonary Embolism and a Patent Foramen Ovale: a Prospective Diffusion-weighted Magnetic Resonance Imaging Study.

Conditions
-----------------
Silent Stroke, Pulmonary Embolism, Patent Foramen Ovale

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pulmonary embolism, informed consent signed, no-contraindication to MRI Exclusion Criteria: contra-indication to MRI, informed consent not obtained

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Incidence of silent stroke in patients with PFO | |
| 2<br>Incidence of silent stroke in patients without PFO | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of cerebral infarcts as detected by Diffusion-weighted MRI |  | during hospitalization | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PFO, stroke, embolism
Knowledge and Attitudes Towards Human Papillomavirus Infections and HPV Vaccination

Study Overview
=================
Brief Summary
-----------------
A better understanding of the target audiences about HPV infection and HPV vaccination would surely allow for a better spread of this vaccination in Switzerland. In order to know if the target audiences are properly informed, we have decided to carry out a study evaluating their level of knowledge on a particular audience that are the men and women undergraduate nurse.

Official Title
-----------------
Knowledge and Attitudes Towards Human Papillomavirus Infections and HPV Vaccination Among Undergraduate Health Students From Switzerland

Conditions
-----------------
HPV-Related Cervical Carcinoma

Intervention / Treatment
-----------------
* Behavioral: knowledge questioannaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible women and men aged between 18-36 years Understands study procedures and accepts voluntarily to participle of the study Exclusion Criteria: .Don't understand french language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 36 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: knowledge questioannaire|, all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire about basic knowledge HPV infection | Percentage of right answer of the questionnaire | 3 months |
Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia

Official Title
-----------------
A Double-blind, Randomized, Multi-center Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of CJ-30061 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Atorvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia

Conditions
-----------------
Hypertension, Hyperlipidemia

Intervention / Treatment
-----------------
* Drug: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
* Drug: Amlodipine 10mg+Valsartan 160mg
* Drug: Valsartan 160mg+Atorvastatin 40mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged between 19 and 74 years Diagnosed with essintial hypertension(average siSBP ≥ 140mmHg) accompanying hyperlipidemia(LDL-C ≥ 100mg/dL) and were on or off treatment at Visit 1(screening) Decided to participate in the study and provided signed informed consent form voluntarily after receiving explanation of the objectives, methods, and effects of the study Exclusion Criteria: Severe hypertension defined as average siDBP ≥ 120mmHg or average siSBP ≥ 200mmHg at Visit 1(screening) The difference in BPs between those measured at the reference arm at Visit 1(screening) was ≥ 10mmHg for siDBP or ≥ 20mmHg for siSBP LDL-C > 250mg/dL or TG ≥ 400mg/dL at Visit 1(screening) Secondary hypertension Diagnosis of type 1 diabetes mellitus(DM) or uncontrolled DM(patients on insulin therapy or patients with HbA1c ≥ 9%)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Test<br>Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg | Drug: Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg<br>* Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg<br>|
| Active Comparator: Reference 1<br>Amlodipine 10mg+Valsartan 160mg | Drug: Amlodipine 10mg+Valsartan 160mg<br>* Amlodipine 10mg+Valsartan 160mg<br>|
| Active Comparator: Reference 2<br>Valsartan 160mg+Atorvastatin 40mg | Drug: Valsartan 160mg+Atorvastatin 40mg<br>* Valsartan 160mg+Atorvastatin 40mg<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in siSBP | Change in siSBP from baseline after 8 weeks of study treatment | baseline and 8 weeks | 
| Change in LDL-C | Change in LDL-C from baseline after 8 weeks of study treatment | baseline and 8 weeks |
The Factors Associated With the Recurrence in Patients With Cushing Disease

Study Overview
=================
Brief Summary
-----------------
Cushing syndrome refers the manifestations induced by chronic glucocorticoid excess and may arise from various causes. Iatrogenic Cushing syndrome accounts for most patients, when they are given exogenous glucocorticoid treatment. In contrast, spontaneous Cushing syndrome results from endogenous glucocorticoid over-secretion. Although Cushing disease is rare, it is the most common cause of spontaneous Cushing syndrome. The patient with Cushing disease has a pituitary corticotroph adenoma, which overproduces adrenocorticotropic hormone (ACTH). ACTH then stimulates adrenal gland to over-secret glucocorticoid. Patients with untreated Cushing disease were shown to have poor prognosis, estimated a 5-year survival rate of 50%. The first line treatment is tumor resection. Other managements include radiotherapy, medication and bilateral adrenalectomy. The initial remission rate is high (66-90%). However, some patients encounter with disease recurrence during follow-up. The aim of this study is to clarify the factors associated with the recurrence after treatment. In this study, we will review the patients with Cushing disease thoroughly and analyze associated predisposing factors. These risk factors can remind the clinical physician to early detect the recurrent disease in these patients, and further prevent morbidity and mortality in their later lives.

Official Title
-----------------
The Factors Associated With the Recurrence in Patients With Cushing Disease

Conditions
-----------------
Cushing Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosed Cushing's disease Exclusion Criteria: Already received treatment in other hospital Ectopic Cushing's syndrome
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with disease persistence or recurrence after surgery, which was determined by clinical symptoms, biochemical lab, dynamic test and image study |  | participants were followed at 3 months after treatment for short-term outcome measure and followed until the last hospital visit, an average of 4.7 years, for long-term outcome measure |